CG ONCOLOGY INC (CGON) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:CGON • US1569441009

49.559 USD
-0.8 (-1.59%)
Last: Feb 9, 2026, 10:00 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

Overall CGON gets a fundamental rating of 3 out of 10. We evaluated CGON against 523 industry peers in the Biotechnology industry. The financial health of CGON is average, but there are quite some concerns on its profitability. CGON is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year CGON has reported negative net income.
  • In the past year CGON has reported a negative cash flow from operations.
CGON Yearly Net Income VS EBIT VS OCF VS FCFCGON Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -20.75%, CGON is in the better half of the industry, outperforming 75.72% of the companies in the same industry.
  • CGON has a Return On Equity of -22.03%. This is amongst the best in the industry. CGON outperforms 82.03% of its industry peers.
Industry RankSector Rank
ROA -20.75%
ROE -22.03%
ROIC N/A
ROA(3y)-25.11%
ROA(5y)N/A
ROE(3y)-27.89%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CGON Yearly ROA, ROE, ROICCGON Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 -10 -20 -30 -40

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for CGON so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CGON Yearly Profit, Operating, Gross MarginsCGON Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 -10K -20K -30K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. Health

2.1 Basic Checks

  • CGON does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • CGON has more shares outstanding than it did 1 year ago.
  • CGON has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CGON Yearly Shares OutstandingCGON Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 20M 40M 60M
CGON Yearly Total Debt VS Total AssetsCGON Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

  • An Altman-Z score of 57.30 indicates that CGON is not in any danger for bankruptcy at the moment.
  • CGON's Altman-Z score of 57.30 is amongst the best of the industry. CGON outperforms 96.94% of its industry peers.
  • A Debt/Equity ratio of 0.00 indicates that CGON is not too dependend on debt financing.
  • The Debt to Equity ratio of CGON (0.00) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 57.3
ROIC/WACCN/A
WACC12.44%
CGON Yearly LT Debt VS Equity VS FCFCGON Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

  • CGON has a Current Ratio of 22.79. This indicates that CGON is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 22.79, CGON belongs to the top of the industry, outperforming 96.56% of the companies in the same industry.
  • CGON has a Quick Ratio of 22.74. This indicates that CGON is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of CGON (22.74) is better than 96.56% of its industry peers.
Industry RankSector Rank
Current Ratio 22.79
Quick Ratio 22.74
CGON Yearly Current Assets VS Current LiabilitesCGON Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 61.58% over the past year.
  • The Revenue has grown by 217.84% in the past year. This is a very strong growth!
  • CGON shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -52.09% yearly.
EPS 1Y (TTM)61.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-90%
Revenue 1Y (TTM)217.84%
Revenue growth 3Y-52.09%
Revenue growth 5YN/A
Sales Q2Q%3774.42%

3.2 Future

  • Based on estimates for the next years, CGON will show a very strong growth in Earnings Per Share. The EPS will grow by 31.81% on average per year.
  • CGON is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 280.24% yearly.
EPS Next Y-56.48%
EPS Next 2Y-36.92%
EPS Next 3Y-18.47%
EPS Next 5Y31.81%
Revenue Next Year79.3%
Revenue Next 2Y479.77%
Revenue Next 3Y389.01%
Revenue Next 5Y280.24%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CGON Yearly Revenue VS EstimatesCGON Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 500M 1B 1.5B 2B 2.5B
CGON Yearly EPS VS EstimatesCGON Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 5 10

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • CGON reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year CGON is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CGON Price Earnings VS Forward Price EarningsCGON Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CGON Per share dataCGON EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6 8

4.3 Compensation for Growth

  • A cheap valuation may be justified as CGON's earnings are expected to decrease with -18.47% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-36.92%
EPS Next 3Y-18.47%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • CGON does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CG ONCOLOGY INC

NASDAQ:CGON (2/9/2026, 10:00:05 AM)

49.559

-0.8 (-1.59%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14
Earnings (Next)03-26
Inst Owners103.59%
Inst Owner Change-0.06%
Ins Owners0.66%
Ins Owner Change0%
Market Cap4.00B
Revenue(TTM)2.17M
Net Income(TTM)-151.48M
Analysts83.81
Price Target82.62 (66.71%)
Short Float %12.8%
Short Ratio8.62
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-7.55%
Min EPS beat(2)-15.32%
Max EPS beat(2)0.21%
EPS beat(4)1
Avg EPS beat(4)-14.42%
Min EPS beat(4)-33.19%
Max EPS beat(4)0.21%
EPS beat(8)3
Avg EPS beat(8)-71%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)1150.64%
Min Revenue beat(2)-100%
Max Revenue beat(2)2401.28%
Revenue beat(4)2
Avg Revenue beat(4)680.33%
Min Revenue beat(4)-100%
Max Revenue beat(4)2401.28%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)13.23%
PT rev (3m)15.38%
EPS NQ rev (1m)0.12%
EPS NQ rev (3m)-4.58%
EPS NY rev (1m)0.07%
EPS NY rev (3m)-1.41%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-15.97%
Revenue NY rev (1m)0%
Revenue NY rev (3m)682.63%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1838.97
P/FCF N/A
P/OCF N/A
P/B 5.81
P/tB 5.94
EV/EBITDA N/A
EPS(TTM)-2.04
EYN/A
EPS(NY)-2.66
Fwd EYN/A
FCF(TTM)-1.45
FCFYN/A
OCF(TTM)-1.45
OCFYN/A
SpS0.03
BVpS8.52
TBVpS8.34
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -20.75%
ROE -22.03%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-25.11%
ROA(5y)N/A
ROE(3y)-27.89%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 56.38%
Cap/Sales 15.46%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 22.79
Quick Ratio 22.74
Altman-Z 57.3
F-Score3
WACC12.44%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)61.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-90%
EPS Next Y-56.48%
EPS Next 2Y-36.92%
EPS Next 3Y-18.47%
EPS Next 5Y31.81%
Revenue 1Y (TTM)217.84%
Revenue growth 3Y-52.09%
Revenue growth 5YN/A
Sales Q2Q%3774.42%
Revenue Next Year79.3%
Revenue Next 2Y479.77%
Revenue Next 3Y389.01%
Revenue Next 5Y280.24%
EBIT growth 1Y-88.51%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-82.61%
EBIT Next 3Y-36.69%
EBIT Next 5YN/A
FCF growth 1Y-221.37%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-220.44%
OCF growth 3YN/A
OCF growth 5YN/A

CG ONCOLOGY INC / CGON FAQ

Can you provide the ChartMill fundamental rating for CG ONCOLOGY INC?

ChartMill assigns a fundamental rating of 3 / 10 to CGON.


Can you provide the valuation status for CG ONCOLOGY INC?

ChartMill assigns a valuation rating of 0 / 10 to CG ONCOLOGY INC (CGON). This can be considered as Overvalued.


What is the profitability of CGON stock?

CG ONCOLOGY INC (CGON) has a profitability rating of 1 / 10.


Can you provide the financial health for CGON stock?

The financial health rating of CG ONCOLOGY INC (CGON) is 6 / 10.